BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

InNexus Inc. Announces Publication Of Scientific Review Of TransMab(TM) Technology


10/19/2005 5:13:14 PM

VANCOUVER, April 7 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., a company empowering the monoclonal antibody, announces the publication of an invited review on TransMab(TM) technology. TransMabs(TM) are monoclonal antibodies to intracellular targets, modified by SuperAntibody Technology ("SAT") to penetrate or translocate into cells, bind to their targets and regulate cellular activities. This technology is the subject of a recently announced collaboration between InNexus and Epitomics, a company using rabbit monoclonal antibodies to create novel diagnostics and therapeutics. The review written by Muller, S., Zhao, Y. Brown, T. L. et al. and entitled "TransMabs: Cell-penetrating antibodies, The next generation" has recently been published in "Expert Opinion on Biological Therapy, volume 5 (2), 2005 pages 237 to 241." It is available online at http://www.ashley-pub.com/.

Commenting on the announcement, Dr. Heinz Kohler, Vice Head of SuperAntibody Research and Development at InNexus, added: "the publication of this review is an acknowledgement of the interest in and novelty of the TransMab(TM) technology." Dr. Charles Morgan, President & CEO of the Company stated, "It is important for the Company to disclose its progress in a peer-reviewed forum so that both the scientific, financial and corporate communities can be apprised of the ongoing validation of SAT. This is a first step in a peer-reviewed process leading to the clinical development and eventually the marketing of this totally new use of monoclonal antibodies. Further announcements will be forthcoming on both internal InNexus and sponsored research and progress towards therapeutic application."

About InNexus

InNexus Biotechnology Inc. is an innovative antibody-driven drug development company that has developed two technology platforms, SuperAntibody(TM) and TransMabs(TM), which respectively improve the potency of existing antibody products and create a novel class of antibody based drug which can penetrate into cells. Both product platforms utilize InNexus's unique, novel and patented methods and technologies allowing InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics to create new markets within multiple disease areas. To learn more about InNexus please visit http://www.innexusbiotech.com/

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.

On behalf of the Board of Directors of InNexus Biotechnology, Inc. "ALTON C. MORGAN" Dr. A. Charles Morgan President Investor Relations: Toll-free: 1-866-990-8382 or 1-888-271-0788 investor@innexusbiotech.com The TSX Venture Exchange has neither approved nor disapproved of the information contained herein.

InNexus Biotechnology, Inc.

CONTACT: Investor Relations: Toll-free: 1-866-990-8382 or1-888-271-0788, investor@innexusbiotech.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES